Codis has agreed to acquire Catalent Pharma Solutions’ Nottingham, UK, facility, expanding its contract development and manufacturing organization (CDMO) capabilities in oral solid dose development ...

French inflammatory diseases specialist Abivax yesterday announced the closing of its previously announced underwritten ...

France-based life sciences venture capital firm Sofinnova today announced that its portfolio company Myricx Bio has reached ...

Sandoz (SDZ: SIX) has launched a direct-to-consumer platform in the USA, taking an unusual step for a global generics and biosimilars manufacturer by allowing self-pay patients to purchase medicines ...

The US Food and Drug Administration (FDA) has issued a warning letter to Genzyme Ireland, a Sanofi (Euronext: SAN) subsidiary, citing significant manufacturing violations at its Waterford biologics ...

Regulators in the USA, Japan, the UK, Switzerland, Australia and several other major international markets have issued a mix of safety statements, review updates, guidance changes, compliance notices ...

A San Francisco-based biotech company developing therapies that address age-related diseases. Founded in 2021 by Joe Betts-LaCroix and initially funded with $180 million from OpenAI CEO Sam Altman, ...

In last week’s news, US biotech Replimune’s resubmitted biologicals license application (BLA) for RP1 (vusolimogene oderparepvec) was accepted by the Food and Drug Administration. On the M&A front, ...

Borealis Bio emerged from stealth in August 2024 with $150 million in combined Series A financing from founding investor Versant Ventures and Novartis AG, as well as committed strategic research ...

India’s Orchid Pharma is in advanced negotiations to out-license its breakthrough antibiotic enmetazobactam in the USA, a move that could mark the company’s commercial entry into the world’s largest ...

Danish drugmaker Novo Nordisk has won conditional UK marketing authorization for Wegovy (semaglutide) in adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-advanced ...

Scribe Therapeutics, a Phase I biotech developing CRISPR therapies for cardiovascular diseases, filed on Thursday with the Securities & Exchange Commission (SEC) to raise up to $75 million in an ...